High-Intensity Focused Ultrasound (HIFU) is a non-invasive medical technology that concentrates acoustic energy from an external transducer onto a precise target inside the body, raising tissue temperature to the point of coagulative necrosis. Cleared applications include prostate tissue ablation, uterine fibroid treatment, and thalamotomy for essential tremor, all without incisions or ionizing radiation.
What is High-Intensity Focused Ultrasound (HIFU)?
HIFU belongs to the broader family of energy-based therapeutic devices: systems that treat disease by delivering focused physical energy rather than a drug or implant. A phased array or bowl-shaped transducer emits ultrasound waves that pass harmlessly through intervening tissue and converge at a focal point, much like a lens focusing sunlight to a single spot. At the focus, acoustic intensity runs thousands of times higher than at the transducer face, generating enough heat to destroy targeted cells within seconds.
HIFU systems sit at the intersection of electromechanical hardware, imaging, and control software. Most platforms pair the ultrasound transducer with magnetic resonance or diagnostic ultrasound imaging so clinicians can see the target and confirm ablation in near real time. Regulators treat HIFU as an active therapeutic device: its safety case rests on how precisely and predictably it deposits energy, not on any pharmacological action.
Why High-Intensity Focused Ultrasound (HIFU) matters in medical device development
The margin for error in HIFU design is narrow. The same acoustic energy that ablates the intended target can injure adjacent nerves, blood vessels, or organs if the focal spot drifts by a few millimeters, so targeting accuracy and real-time monitoring carry direct patient-safety weight. Regulators respond accordingly: HIFU platforms typically enter the US market as Class II devices and the EU market as Class IIb active therapeutic devices under EU MDR 2017/745, requiring a full technical file, clinical evaluation, and post-market surveillance.
Sponsors have used both the De Novo and 510(k) pathways for different HIFU indications, but each new indication, whether prostate ablation, fibroid treatment, or pain palliation for bone metastases, generally needs its own clinical evidence tying energy dose to a defined safety outcome. Under-specifying verification against IEC 60601-2-62 or the treatment planning software early tends to surface late, during design freeze or FDA review, when fixes cost the most.
How High-Intensity Focused Ultrasound (HIFU) works
A HIFU system has three functional layers: an acoustic source, an imaging and targeting subsystem, and treatment planning software.
- Transducer and energy source. A single-element or multi-element phased-array transducer converts electrical signals into ultrasound waves, typically in the low megahertz range, shaped to converge at a set focal depth.
- Imaging guidance. Magnetic resonance imaging or diagnostic ultrasound locates the target, sets a safety margin around critical structures, and, in MR-guided systems, tracks temperature in real time via MR thermometry.
- Treatment planning software. The operator defines the target volume and exposure parameters; the software sequences individual sonications, or energy pulses, across the target.
- Thermal and mechanical effects. Absorbed acoustic energy raises tissue temperature past the threshold for coagulative necrosis, and some systems add a mechanical, cavitation-based effect from short high-pressure pulses.
IEC 60601-2-62 is the particular standard for high-intensity therapeutic ultrasound equipment. It amends IEC 60601-1 with requirements specific to focused ultrasound output, and the companion specification IEC 62556 defines how to measure the acoustic field parameters it requires. Risk management still runs under ISO 14971, usability under IEC 62366-1, and software, including treatment planning and closed-loop control, under IEC 62304.
Common challenges and best practices
Acoustic field verification is harder than it looks. Side lobes and near-field heating can deposit unintended energy outside the nominal focal spot, so field characterization per IEC 62556 needs to happen early, not as a pre-submission afterthought. Teams that leave this late often find margin problems after tooling is locked.
Predicate selection is another recurring snag. HIFU indications have cleared through a mix of 510(k) and De Novo routes, so a device for a new anatomical target may lack a clean predicate, forcing a heavier-evidence De Novo submission than planned.
Software governance is easy to underestimate. Treatment planning and real-time control software directly affect where energy lands, which puts it inside IEC 62304 and usability scope, not general software QA alone. The strongest programs write risk-to-requirement traceability for the software at the same time as the acoustic design, rather than adding it once the hardware is stable.
How SJML helps with High-Intensity Focused Ultrasound (HIFU)
SJML supports HIFU and other focused-ultrasound programs across the device lifecycle. Its design and engineering teams work across mechanical, electronics, embedded systems, and software, with in-house labs for electrical safety and IEC 60601 testing that extend to particular standards like IEC 60601-2-62. Risk management under ISO 14971 and usability engineering under IEC 62366-1 are built into development rather than added afterward. For software-driven treatment planning and control, SJML’s QARA team supports IEC 62304 lifecycle documentation alongside regulatory strategy, technical file preparation, and clinical evaluation for FDA and EU MDR submissions.
Talk to SJML’s engineering team →
Frequently asked questions
HIFU stands for High-Intensity Focused Ultrasound, a non-invasive technology that focuses acoustic energy at a precise point inside the body to heat and destroy targeted tissue. It differs from diagnostic ultrasound, which uses low-intensity waves to produce images rather than treat tissue, and from radiofrequency or laser ablation, which use other energy types to reach a similar clinical goal.
Yes, for specific indications. The FDA has cleared or approved HIFU systems for applications including MR-guided uterine fibroid ablation, prostate tissue ablation, and thalamotomy for essential tremor, generally through the 510(k) or De Novo pathway. Clearance is indication-specific: a HIFU platform approved for one use is not automatically authorized for another, since each indication needs its own clinical and technical evidence package.
Both are thermal ablation methods, but HIFU delivers energy from outside the body through an external transducer, with no probe placed in the tissue, while radiofrequency ablation typically requires inserting an electrode into or near the target. HIFU’s non-contact delivery depends heavily on precise focusing and imaging guidance, while radiofrequency systems rely more on electrode placement accuracy and impedance monitoring.
IEC 60601-2-62 sets particular safety and performance requirements for high-intensity therapeutic ultrasound equipment, building on the general standard IEC 60601-1. IEC 62556 supports it by defining acoustic field measurement methods. Alongside these, ISO 14971 governs risk management, IEC 62366-1 covers usability engineering, and IEC 62304 applies to any treatment planning or control software the system includes.
Related terms
- Radiofrequency Ablation
- MR-Guided Focused Ultrasound (MRgFUS)
- IEC 60601-1
- Software as a Medical Device (SaMD)
- Risk Management File
